Physician profile
Brian How
NPI 1730765983
$5,735.82
in general payments reported to CMS, 2019-2025
23 companies · $1,874 in 2025
The $1,874 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $266 · 2023: $1,475 · 2024: $2,121 · 2025: $1,874.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,375 · Education: $94.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,374.70 |
| Education | $94.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $672.59 | 2023-2025 | Dupixent |
| Janssen Biotech, INC. | $597.14 | 2023-2025 | Tremfya |
| Genzyme Corporation | $577.62 | 2023-2025 | |
| E.R. Squibb & Sons, L.L.C. | $493.51 | 2022-2024 | Sotyktu |
| Abbvie INC. | $474.77 | 2023-2025 | |
| Lilly USA, LLC | $385.38 | 2022-2025 | Olumiant, Taltz, Ebglyss |
| Pfizer INC. | $362.65 | 2024 | |
| Incyte Corporation | $282.50 | 2023-2025 | Opzelura |
| Leo Pharma INC. | $230.32 | 2025 | Anzupgo |
| Novartis Pharmaceuticals Corporation | $225.53 | 2023-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $216.18 | 2024-2025 | Spevigo, Cyltezo |
| Ucb, INC. | $200.92 | 2024-2025 | Bimzelx |
| Biofrontera INC. | $193.50 | 2023-2024 | Xepi, Bf-Rhodoled, Ameluz |
| Sun Pharmaceutical Industries INC. | $156.11 | 2022-2023 | Winlevi, Absorica Ld, Ilumya |
| Dermavant Sciences, INC. | $154.15 | 2023-2024 | Vtama |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $148.85 | 2023-2024 | Siliq, Cabtreo |
| Janssen Scientific Affairs, LLC | $133.33 | 2025 | Tremfya |
| Almirall LLC | $80.00 | 2025 | Klisyri |
| Organon LLC | $58.26 | 2025 | Vtama |
| Verrica Pharmaceuticals INC. | $27.59 | 2024 | Ycanth |
| Helsinn Therapeutics (U.S.), INC. | $23.21 | 2023 | Valchlor |
| Arcutis Biotherapeutics, INC. | $21.38 | 2025 | Zoryve |
| Botanix Sb INC | $20.33 | 2025 | Sofdra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian How listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.